2013
Longer-term cardiac safety and outcomes of dose dense (dd) doxorubicin and cyclophosphamide (AC) followed by paclitaxel (T) and trastuzumab (H) with and without lapatinib (L) in patients (pts) with early breast cancer (BC).
Iyengar N, Morris P, Patil S, Chen C, Abbruzzi A, Lehman R, Steingart R, Oeffinger K, Lin N, Moy B, Come S, Winer E, Norton L, Hudis C, Dang C. Longer-term cardiac safety and outcomes of dose dense (dd) doxorubicin and cyclophosphamide (AC) followed by paclitaxel (T) and trastuzumab (H) with and without lapatinib (L) in patients (pts) with early breast cancer (BC). Journal Of Clinical Oncology 2013, 31: 167-167. DOI: 10.1200/jco.2013.31.26_suppl.167.Peer-Reviewed Original ResearchLeft ventricular ejection fractionCongestive heart failureDistant disease-free survivalEarly breast cancerBreast cancerHER2-positive early breast cancerMedian left ventricular ejection fractionLong-term cardiac safetyRandomized phase III studyEarly-stage breast cancerLong-term cardiac toxicityTrial BTrial AAnthracycline-based regimensDose-dense doxorubicinPre-existing hypertensionPhase II studyDisease-free survivalPhase III studyVentricular ejection fractionStage breast cancerDd ACMonths 44II studyIII studyLong‐term cardiac safety and outcomes of dose‐dense doxorubicin and cyclophosphamide followed by paclitaxel and trastuzumab with and without lapatinib in patients with early breast cancer
Morris PG, Iyengar NM, Patil S, Chen C, Abbruzzi A, Lehman R, Steingart R, Oeffinger KC, Lin N, Moy B, Come SE, Winer EP, Norton L, Hudis CA, Dang CT. Long‐term cardiac safety and outcomes of dose‐dense doxorubicin and cyclophosphamide followed by paclitaxel and trastuzumab with and without lapatinib in patients with early breast cancer. Cancer 2013, 119: 3943-3951. PMID: 24037735, DOI: 10.1002/cncr.28284.Peer-Reviewed Original ResearchConceptsDistant disease-free survivalCongestive heart failureEarly breast cancerHuman epidermal growth factor receptor 2Breast cancerTrial ALong-term cardiac safetyEpidermal growth factor receptor 2Dose-dense doxorubicinDose-dense chemotherapyAnti-HER2 therapyDisease-free survivalPhase 2 trialGrowth factor receptor 2Long-term incidenceFactor receptor 2Previous hypertensionCumulative incidenceHeart failureAdditional patientsCardiac safetyLower riskReceptor 2PatientsTrial B.Longer-term cardiac safety and outcomes of dose dense (dd) doxorubicin and cyclophosphamide (AC) followed by paclitaxel (T) and trastuzumab (H) with and without lapatinib (L) in patients (pts) with early breast cancer (BC).
Morris P, Iyengar N, Patil S, Chen C, Abbruzzi A, Lehman R, Steingart R, Oeffinger K, Lin N, Moy B, Come S, Winer E, Norton L, Hudis C, Dang C. Longer-term cardiac safety and outcomes of dose dense (dd) doxorubicin and cyclophosphamide (AC) followed by paclitaxel (T) and trastuzumab (H) with and without lapatinib (L) in patients (pts) with early breast cancer (BC). Journal Of Clinical Oncology 2013, 31: 630-630. DOI: 10.1200/jco.2013.31.15_suppl.630.Peer-Reviewed Original ResearchLeft ventricular ejection fractionCongestive heart failureDistant disease-free survivalEarly breast cancerBreast cancerHER2-positive early breast cancerMedian left ventricular ejection fractionLong-term cardiac safetyMedian f/uRandomized phase III studyEarly-stage breast cancerLong-term cardiac toxicityTrial BTrial AAnthracycline-based regimensCompletion of ACDose-dense doxorubicinPre-existing hypertensionDisease-free survivalPhase II studyPhase III studyVentricular ejection fractionStage breast cancerDd ACMonths 44Lumpectomy Plus Tamoxifen With or Without Irradiation in Women Age 70 Years or Older With Early Breast Cancer: Long-Term Follow-Up of CALGB 9343
Hughes KS, Schnaper LA, Bellon JR, Cirrincione CT, Berry DA, McCormick B, Muss HB, Smith BL, Hudis CA, Winer EP, Wood WC. Lumpectomy Plus Tamoxifen With or Without Irradiation in Women Age 70 Years or Older With Early Breast Cancer: Long-Term Follow-Up of CALGB 9343. Journal Of Clinical Oncology 2013, 31: 2382-2387. PMID: 23690420, PMCID: PMC3691356, DOI: 10.1200/jco.2012.45.2615.Peer-Reviewed Original ResearchMeSH KeywordsAgedAged, 80 and overAntineoplastic Agents, HormonalBiomarkers, TumorBreast NeoplasmsFemaleFollow-Up StudiesHumansKaplan-Meier EstimateMastectomy, SegmentalNeoplasm Recurrence, LocalNeoplasm StagingOdds RatioRadiotherapy, AdjuvantReceptors, EstrogenTamoxifenTime FactorsTreatment OutcomeConceptsBreast cancer-specific survivalEarly-stage breast cancerCancer-specific survivalOverall survivalBreast cancerRadiation therapyRegional recurrenceDistant metastasisER-positive early-stage breast cancerDistant disease-free survivalWomen age 70 yearsEstrogen receptor-positive breast carcinomasFrequency of mastectomyTen-year OSAdjuvant radiation therapyPrimary end pointDisease-free survivalEarly breast cancerAge 70 yearsBreast-conserving surgeryBreast preservationCALGB 9343Locoregional recurrenceTAM groupLocal recurrence
2005
Optimizing Adjuvant Endocrine Therapy in Postmenopausal Women With Early-Stage Breast Cancer: A Decision Analysis
Punglia RS, Kuntz KM, Winer EP, Weeks JC, Burstein HJ. Optimizing Adjuvant Endocrine Therapy in Postmenopausal Women With Early-Stage Breast Cancer: A Decision Analysis. Journal Of Clinical Oncology 2005, 23: 5178-5187. PMID: 15998905, DOI: 10.1200/jco.2005.02.964.Peer-Reviewed Original ResearchConceptsDisease-free survivalDisease-free survival estimatesAromatase inhibitor monotherapyYears of tamoxifenAromatase inhibitorsSequential therapyBreast cancerInhibitor monotherapyPostmenopausal womenTreatment strategiesHormone receptor-positive breast cancerDisease-free survival ratesDistant disease-free survivalReceptor-positive breast cancerEarly-stage breast cancerSurvival estimatesAdjuvant endocrine therapyAromatase inhibitor therapyCross-over treatmentNode-positive patientsSequential adjuvant therapyPostmenopausal breast cancerRelative risk reductionRandomized clinical trialsSequential treatment strategyPrognosis after local recurrence after conservative surgery and radiation for early-stage breast cancer
Galper S, Blood E, Gelman R, Abner A, Recht A, Kohli A, Wong JS, Smith D, Bellon J, Connolly J, Schnitt S, Winer E, Silver B, Harris JR. Prognosis after local recurrence after conservative surgery and radiation for early-stage breast cancer. International Journal Of Radiation Oncology • Biology • Physics 2005, 61: 348-357. PMID: 15667952, DOI: 10.1016/j.ijrobp.2004.06.011.Peer-Reviewed Original ResearchConceptsLocal recurrenceConservative surgeryBreast cancerDistant metastasisInitial diagnosisRadiation therapyEarly-stage invasive breast cancerDistant disease-free survivalEarly-stage breast cancerClinical stage IDisease-free survivalFinal study populationInvasive breast cancerLong-term prognosisProportional hazards modelNonbreast malignanciesActuarial freedomMedian followDistant failureSecond malignanciesIpsilateral breastLocal therapyRegional nodalMedian timeStudy population